• Home
  • Antibody Discovery Services
  • Applications
  • Technologies
  • Resources
  • Contact Us
  • 中文 / CN
  • Deutsch / DE
  • 日本語 / JP
  • 한글 / KR
Antibody Discovery Services
  • Hybridoma Platform
  • Single B Cells Platform
  • Phage & Yeast Display
  • Lead Optimization

WuXi Biologics

Offering End-to-End Solutions

  • Antibody Discovery Services
    • Hybridoma Platform
    • Single B Cells Platform
    • Phage & Yeast Display
    • Lead Optimization
  • Applications
  • Technologies
  • Resources
CN
DE
Contact Us
菜单
  • Home
  • Antibody Discovery Services
    • Hybridoma Platform
    • Single B Cells Platform
    • Phage & Yeast Display
    • Lead Optimization
  • Applications
  • Technologies
  • Resources
  • Contact Us
  • 中文 / CN
  • Deutsch / DE
  • 日本語 / JP
  • 한글 / KR
Telephone sharing button Contact Us linkedin sharing button Linked In wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

WuXi Biologics Offering End-to-End Solutions

Discovery From Target to Drug Candidate

Development 12 Months from DNA to IND

Manufacturing Global Dual Sourcing

  • WuXi Biologics Offering End-to-End Solutions

  • Discovery From Target to Drug Candidate

  • Development 12 Months from DNA to IND

  • Manufacturing Global Dual Sourcing

Services
& Solutions

A global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics.

Technologies

Technology platforms that span the entire drug discovery to manufacturing spectrum.

WuXi XDC

A WuXi Biologics subsidiary, greatly simplifies bioconjugate development and manufacturing.

Mammalian

Unparalleled capacities and expertise for the discovery, development and cGMP manufacture of biologics from concept to commercialization.

Testing

Providing extensive expertise and high-quality biosafety testing under EMA, ISO (CNAS) and CMA certified laboratories.

Microbial

 E. coli and yeast based expression systems, process development and cGMP manufacturing platform

Quality

World-class quality systems approved by the U.S. FDA, EMA and NMPA.

Viral

Viral vector based vaccine and therapeutic virus development and cGMP manufacturing platform.

Locations

Total estimated capacity for biopharmaceutical production in China, Ireland, the U.S., Germany and Singapore to exceed 580,000 liters by 2026.

United States
Massachusetts
U.S.
189,500sq. ft.
Operational2024
L‌earn M‌ore
New Jersey
U.S.
66,000sq. ft.
Operational2021
L‌earn M‌ore
Pennsylvania
U.S.
33,000sq. ft.
OperationalOctober. 2020
L‌earn M‌ore
Ireland
Dundalk
Ireland
26Hectare campus
Operational2022
L‌earn M‌ore
WuXi Vaccines
Ireland
$240Million investment
Operational2022
L‌earn M‌ore
Germany
Leverkusen
Germany
13,000+sq.m. facility
Operations2020
L‌earn M‌ore
Wuppertal
Germany
30,000+sq.m.
Operations2021
L‌earn M‌ore
Singapore
Singapore
$1.4Billion investment
OverTen Years
L‌earn M‌ore
China
Shanghai
Waigaoqiao Free Trade Zone
200,000 sq.ft
Opened April 2018
L‌earn M‌ore
Shanghai
Fengxian District
1.6 millionsq. ft.
Planned2021
L‌earn M‌ore
Wuxi
15,296sq.m.
OpenedOctober 2012
L‌earn M‌ore
Suzhou
16,000sq. m.
OpenedDecember 2014
L‌earn M‌ore
Hangzhou
30,000sq. m.
Operations2021
L‌earn M‌ore
Chengdu
314,000sq. m.
Planned2023
L‌earn M‌ore
Shijiazhuang
82,160sq. m.
Planned2022
L‌earn M‌ore
Hangzhou
50,000sq. m.
Operations2021
L‌earn M‌ore
Suzhou
11,500sq. m.
Operations2021
L‌earn M‌ore

Latest News

L‌earn M‌ore
  • News
    Apr. 29, 2025
    Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
  • News
    Apr. 22, 2025
    WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
  • News
    Apr. 17, 2025
    WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
  • News
    Apr. 29, 2025
    Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
  • News
    Apr. 22, 2025
    WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
  • News
    Apr. 17, 2025
    WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
  • News
    Apr. 29, 2025
    Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
  • News
    Apr. 22, 2025
    WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
  • News
    Apr. 17, 2025
    WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
Contact your local sales representative
L‌earn M‌ore
  • Navigation
    About Us
    Services & Solutions
    Careers
    Investor Relations
    News & Media
  • Term of Use
    Privacy Policy
    Cookies Policy
  • Contact
    Email: info@wuxibiologics.com
    Compliance Reporting
    Email: IA_biologics@wuxibiologics.com
    Careers
    Email: Recruiting_Biologics@wuxibiologics.com

Copyright © 2022 WuXi Biologics. All Rights Reserved. 苏ICP备16033595号 China national emblem苏公网安备 32021102001100号

We use cookies that are necessary for our website to function properly. We also use cookies to retain user preferences, for analysing our website traffic and for statistical and web-traffic marketing purposes. By clicking “accept all”, you provide your specific and active consent for the use of last-mentioned categories of cookies. To see a list of the cookies and their purpose, click here. Please see section 6 in our Privacy Policy for more information on (i) how we use cookies and (ii) your rights and actions in relation to data protection.
Accept All